Profile data is unavailable for this security.
About the company
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
- Revenue in EUR (TTM)0.00
- Net income in EUR-8.03m
- Incorporated2006
- Employees18.00
- LocationBiophytis SA14 avenue de l'OperaPARIS 75001FranceFRA
- Phone+33 141836600
- Websitehttps://www.biophytis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GeNeuro SA | 0.00 | -14.76m | 916.64k | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| IntegraGen SA | 6.69m | -1.55m | 1.02m | 39.00 | -- | 2.88 | -- | 0.1523 | -0.2338 | -0.2338 | 1.01 | 0.0526 | 1.36 | 8.98 | 4.92 | 171,592.60 | -31.48 | -1.90 | -115.71 | -4.51 | 59.50 | 64.12 | -23.12 | -1.44 | 0.9581 | -- | 0.5447 | -- | -30.62 | 0.9904 | -49.22 | -- | -- | -- |
| Biophytis SA | 0.00 | -8.03m | 2.52m | 18.00 | -- | -- | -- | -- | -0.8431 | -0.8431 | 0.00 | -0.3326 | 0.00 | -- | -- | 0.00 | -104.73 | -99.99 | -- | -808.35 | -- | -- | -- | -- | -- | -34.32 | -- | -- | -- | -- | 39.04 | -- | -12.94 | -- |
| Quantum Genomics SA | 0.00 | -8.89m | 5.03m | 2.00 | -- | -- | -- | -- | -0.1276 | -0.1276 | 0.00 | -0.0352 | 0.00 | -- | -- | 0.00 | -433.64 | -70.24 | -858.41 | -123.45 | -- | -3,200.37 | -- | -3,364.53 | -- | -131.86 | 14.44 | -- | -100.00 | -- | -180.44 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 941.74k | 318.01k | 9.38m | 16.00 | 30.12 | 0.9971 | 10.62 | 9.96 | 0.2776 | 0.2776 | 0.8377 | 8.38 | -- | -- | -- | 58,858.75 | -- | -1.51 | -- | -1.96 | 144.97 | 128.32 | 33.77 | -13.36 | 0.3156 | -- | 0.2867 | -- | 14.61 | 10.44 | 1,081.17 | -- | -- | -- |
| Oncodesign Precision Medicine Opm SA | 207.25k | 6.27m | 9.99m | 13.00 | 1.56 | 0.9421 | 1.53 | 48.19 | 0.3457 | 0.3457 | 0.0114 | 0.5732 | 0.0119 | -- | 0.2634 | 11,513.89 | 36.11 | -- | 54.21 | -- | 6,372.89 | -- | 3,026.21 | -- | 0.926 | 20.81 | 0.3859 | -- | -80.69 | -- | 10.89 | -- | -- | -- |
| Predilife SA | 728.07k | -3.80m | 12.42m | 27.00 | -- | -- | -- | 17.06 | -0.9936 | -0.9936 | 0.1905 | -1.26 | 0.3919 | -- | 3.63 | 36,421.71 | -204.34 | -93.24 | -- | -132.80 | 98.10 | 89.32 | -521.48 | -1,377.00 | -- | -19.99 | -- | -- | 55.20 | 84.82 | -0.9621 | -- | -24.35 | -- |
Data as of Feb 06 2026. Currency figures normalised to Biophytis SA's reporting currency: Euro EUR
